Amneal Pharmaceuticals vs ANI Pharmaceuticals
AMRX and ANIP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRX and ANIP compare
Amneal Pharmaceuticals is the larger company, worth 4.2 times as much as ANI Pharmaceuticals ($6.8B against $1.6B).
On earnings, ANI Pharmaceuticals is cheaper: it trades at 13.5× trailing earnings, against 50.9× for Amneal Pharmaceuticals.
ANI Pharmaceuticals grew revenue faster over the last twelve months (25.9% versus 8.9% for Amneal Pharmaceuticals).
ANI Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 11.2% compared with 4.2% at Amneal Pharmaceuticals.
ANI Pharmaceuticals scores higher on the StockData Score (15 against 12 for Amneal Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRX | ANIP |
|---|---|---|
| Size and price | ||
| Market cap | $6.8B | $1.6B |
| Share price | $21.38 | $71.44 |
| Change, 1 year | 79.7% | −18.1% |
| Change, 5 years | 363% | 64.1% |
| Beta (5Y) | 1.07 | 0.61 |
| Employees | 8,500 | 970 |
| StockData Score | ||
| Total score | 12 | 15 (better) |
| Valuation score | 0 | 5 (better) |
| Growth score | 5 (better) | 2 |
| Performance score | 5 (better) | 4 |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 50.9× | 13.5× (better) |
| P/S | 2.1× | 1.6× (better) |
| P/B | 12.9× | 2.6× (better) |
| EV/EBITDA | 20.1× | 6.1× (better) |
| P/FCF | 77.4× | 8.0× (better) |
| FCF yield | 1.3% | 12.5% (better) |
| Fair value | $13.10 | $153.69 |
| Margin of safety | −63.2% | 53.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.9% | 25.9% (better) |
| Revenue growth, 5Y average | 8.7% | 33.5% (better) |
| Net income growth (TTM) | 2159% (better) | 188% |
| EPS growth (TTM) | 2000% (better) | 225% |
| EPS growth, 5Y average | −18.5% | – |
| Profitability | ||
| Gross margin | 40.2% | 61.1% (better) |
| Operating margin | 15.0% | 16.0% (better) |
| Net margin | 4.2% | 11.2% (better) |
| FCF margin | 2.8% | 19.7% (better) |
| Return on equity | 63.2% (better) | 20.4% |
| Return on invested capital | 16.3% | 23.0% (better) |
| Financial health | ||
| Debt / equity | 5.53 | 0.47 (better) |
| Net debt / EBITDA | 5.81 (better) | −0.49 |
| Interest coverage | – | 5.4× |
| Current ratio | 1.87 | 2.75 (better) |
| Altman Z-score | 1.88 | 2.57 (better) |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Payout ratio | – | 0.00% |
| Buyback yield | – | 1.2% |
| Shareholder yield | 0.00% | 1.2% (better) |
| Ownership | ||
| Held by institutions | 52.7% | 100% |
| Held by insiders | 60.7% | 12.3% |
| Insider net buying, 12 months | −$7.7M (better) | −$13.6M |
| Short interest, % of float | 9.1% | 17.8% |
Go deeper
- AMRX stock overview
- AMRX income statement
- AMRX valuation and score
- ANIP stock overview
- ANIP income statement
- ANIP valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.